Levels of total tau and tau protein phosphorylated at threonine 181 in patients with incipient and manifest Alzheimer's disease

Schönknecht, Peter; Pantel, Johannes; Hunt, Aoife; Volkmann, Martin; Büerger, Katharina; Hampel, Harald; Schröder, Johannes

doi:10.1016/s0304-3940(02)01481-7

Cited by 55 publications

(36 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Levels of total tau protein and tau protein phosphorylated at threonine 181 differentiate patients with incipient and manifest AD [44,45] . According to a recent meta-analysis, at present, CSF neurofilament levels cannot be recommended for screening purposes in the diagnosis of dementia, because of the rather small effect size.…”

Section: Discussionmentioning

confidence: 99%

Cerebrospinal Fluid Concentrations of Functionally Important Amino Acids and Metabolic Compounds in Patients with Mild Cognitive Impairment and Alzheimer’s Disease

et al. 2010

View full text Add to dashboard Cite

Cerebrospinal fluid (CSF) biomarkers play an important role in the differential diagnosis of neurodegenerative diseases such as Alzheimer’s disease (AD) and its postulated precursor stage mild cognitive impairment (MCI). While CSF tau protein, phospho-tau protein and β-amyloid have become part of the diagnostic process in clinical routine, the importance of several other biomarkers remains quite unclear. Among these, amino acids and metabolic compounds have been studied in clinical conditions mostly other than AD and, to our knowledge, never in MCI. In patients with AD (n = 14) and MCI (n = 13) we now determined CSF levels of 36 different amino acids and metabolic compounds by high-performance liquid chromatography. We found that 8 out of 36 amino acids (urea, threonine, glutamate, citrulline, α-aminobutyric acid, ornithine, ammonia and arginine) were significantly elevated in the CSF of patients with AD compared to those with MCI. As most of these amino acids and metabolic compounds are functionally important for brain-specific metabolic processes, neurotransmitter pathways or compensatory mechanisms, our findings might reflect these changes occurring within the brain of patients with MCI and those who developed manifest AD.

show abstract

Section: Discussionmentioning

confidence: 99%

Cerebrospinal Fluid Concentrations of Functionally Important Amino Acids and Metabolic Compounds in Patients with Mild Cognitive Impairment and Alzheimer’s Disease

et al. 2010

View full text Add to dashboard Cite

show abstract

“…The most promising aspect of this marker is its potential for distinguishing between AD and other dementias including tauopathies. The presently known biological markers in CSF are A ␤ [4,5] , tau protein and phospho-tau protein [6][7][8][9][10] . However, differential diagnosis between AD and non-AD dementias has been an important problem both clinically and biologically, as tau and phospho-tau are established markers.…”

Section: Discussionmentioning

confidence: 99%

“…Current approaches focus on 2 major protein aggregates in the AD brain, A ␤ and phosphorylated microtubule-associated tau protein (phospho-tau), as reflected by senile plaques and neurofibrillary tangles, respectively. In cerebrospinal fluid (CSF), the levels of A ␤ 42 , which ends at amino acid 42, are significantly decreased in AD patients [4,5] , while excess levels of phospho-tau have been observed [6][7][8][9][10] . The levels of these proteins in CSF reflect their metabolism in the central nervous system.…”

mentioning

confidence: 99%

Sugar Chains of Cerebrospinal Fluid Transferrin as a New Biological Marker of Alzheimer’s Disease

Taniguchi

Okayama

Hashimoto

et al. 2008

Dement Geriatr Cogn Disord

View full text Add to dashboard Cite

Background/Aims: Alzheimer’s disease (AD) is a well-known type of dementia. However, it remains difficult to identify AD in the early stage and to distinguish it from other dementing disorders. We examined glycoproteins in cerebrospinal fluid (CSF) as potential biological markers of AD. Methods: CSF samples were collected from AD, other dementia and nondemented patients. Glycoproteins in CSF were detected by lectin blotting using wheat germ agglutinin (WGA), and sugar chain analysis was performed by isoelectric focusing. Results: In Alzheimer’s CSF, several glycoproteins had lower WGA-binding activities, one of which was sufficiently sensitive and specific to distinguish AD from nondemented controls and other dementias. Further analysis identified this glycosylated protein as transferrin, and altered sugar chain composition of transferrin isoforms was observed despite normal protein levels in CSF. Conclusion: The decreased WGA-binding activity of transferrin in AD is probably due to altered glycosylation of transferrin molecules. Transferrin glycosylation is thus a potential biological marker for AD diagnosis, and changes in this glycosylation may play an important role in the pathophysiology of AD.

show abstract

“…CSF biomarkers included total soluble amyloid precursor proteins (sAPP) α and β, amyloid β (Aβ) 1-38 , Aβ 1-42 [32], and phosphorylated tau (p-tau) [29]. We also measured lipocalin-type prostaglandin D synthase (L-PGDS)/β-trace and cystatin C, a known chaperone of Aβ protein.…”

Section: Csf Analysismentioning

confidence: 99%

Cerebrospinal fluid biomarkers for prognosis of long-term cognitive treatment outcomes in patients with idiopathic normal pressure hydrocephalus

Nakajima

Miyajima

Ogino

et al. 2015

Journal of the Neurological Sciences

View full text Add to dashboard Cite

The prognosis of cognitive improvement after cerebrospinal fluid (CSF) shunting in idiopathic normal pressure hydrocephalus (iNPH) remains uncertain, with no reports on CSF biomarkers related to long-term cognitive prognosis. We performed a preliminary study of CSF biomarker protein levels for cognitive outcome prognostication of two-year outcomes after shunt treated iNPH in 36 patients (13 women) with a median age of 75years (IQR 69-78). CSF biomarkers included soluble amyloid precursor proteins (sAPP, sAPPα, sAPPβ), amyloid β (Aβ)1-38, Aβ1-42 and phosphorylated tau (p-tau), lipocalin-type prostaglandin D synthase (L-PGDS)/β-trace, and cystatin C. The results clearly showed that p-tau levels (sensitivity of 71.4%, specificity of 77.8%, cut-off value of 22.0pg/mL), Aβ1-38/Aβ1-42 ratio (77.8%, 81%, 3.58), and the Aβ1-42/p-tau ratio (76%, 72.7%, 14.6) in preoperative CSF have the potential to determine postoperative prognosis. Improved cognition may be associated with the improvement in CSF circulation after LPS, which likely induces cystatin C and L-PGDS and switches synthesis from Aβ1-42 to Aβ1-38.

show abstract

Levels of total tau and tau protein phosphorylated at threonine 181 in patients with incipient and manifest Alzheimer's disease

Cited by 55 publications

References 13 publications

Cerebrospinal Fluid Concentrations of Functionally Important Amino Acids and Metabolic Compounds in Patients with Mild Cognitive Impairment and Alzheimer’s Disease

Cerebrospinal Fluid Concentrations of Functionally Important Amino Acids and Metabolic Compounds in Patients with Mild Cognitive Impairment and Alzheimer’s Disease

Sugar Chains of Cerebrospinal Fluid Transferrin as a New Biological Marker of Alzheimer’s Disease

Cerebrospinal fluid biomarkers for prognosis of long-term cognitive treatment outcomes in patients with idiopathic normal pressure hydrocephalus

Contact Info

Product

Resources

About